Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Dyadic International, Inc. (NASDAQ: DYAI) will report its financial results for the first quarter of 2023 on May 10, 2023, at 5:00 p.m. ET. This follows the company's focus on innovative microbial platforms aimed at increasing global protein bioproduction and improving access to biopharmaceutical products for human and animal health. Dyadic utilizes advanced technology based on the fungus Thermothelomyces heterothallica, enhancing the development and manufacturing of biologics. Their lead asset, DYAI-100, is a COVID-19 vaccine candidate, showcasing the company's commitment to addressing unmet clinical needs. A webcast of the conference call will be available post-event for investors and stakeholders.
Dyadic International, Inc. (NASDAQ: DYAI) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled "PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA." This patent is expected to provide protection through 2038 and covers the development and manufacture of seasonal and pandemic influenza vaccines using Dyadic’s C1 protein production platform. The human influenza vaccine market is valued at approximately $8 billion, projected to exceed $12 billion by 2028. CEO Mark Emalfarb highlighted the urgent need for efficient vaccine manufacturing platforms, especially in light of recent health crises. The patent strengthens Dyadic's intellectual property, bolstering its capacity to produce antigens and therapeutic proteins across diverse applications including oncology and diabetes.